Vertex Pharmaceuticals (WBO:VRTX) Accounts Payable & Accrued Expense : €3,142 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Accounts Payable & Accrued Expense?

Vertex Pharmaceuticals's quarterly accounts payable & accrued expense declined from Sep. 2024 (€3,258 Mil) to Dec. 2024 (€3,089 Mil) but then increased from Dec. 2024 (€3,089 Mil) to Mar. 2025 (€3,142 Mil).

Vertex Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2022 (€2,294 Mil) to Dec. 2023 (€2,974 Mil) and increased from Dec. 2023 (€2,974 Mil) to Dec. 2024 (€3,089 Mil).

Vertex Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Vertex Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Accounts Payable & Accrued Expense Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1,282.40

1,658.14

2,294.49

2,973.56

3,088.57

Vertex Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2,895.52	3,035.88	3,257.57	3,088.57	3,142.04

Vertex Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Vertex Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VX1:Germany VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.